New website aims to close cancer care gap for black patients
NCT ID NCT05034289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to see if the website was acceptable and helpful in empowering patients to make informed decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
81 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
May 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria Patient Key Informant: * Age 18 and older * Self-identify as Black/African American * Diagnosed with solid tumor * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Relative Key Informant: * Age 18 and older * Spouse, blood relative, or caregiver of a cancer patient who identifies as Black/African American * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Provider Key Informant: * Age 18 and older * Physician, nurse, social worker, patient navigator, or financial counselor * Work in oncology setting * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Pilot Tester: * Age 18 and older * Self-identify as Black/African American * Able to read and speak English fluently * Able to provide informed consent * Newly diagnosed with solid tumor cancer (Stage I-IV) * Have not yet consulted with an oncologist regarding treatment * Able to complete 2 surveys and an in-depth interview Exclusion Criteria Key informants will be excluded from the study if they do not meet the inclusion criteria. Pilot testers will be excluded from the study if they previously participated as key informants and do not meet inclusion criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinical trials are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors